<DOC>
	<DOCNO>NCT02206789</DOCNO>
	<brief_summary>Aim/ Objective : Study consist 2 separate distinct entity A . Evaluation efficacy 2 % cyclosporine prevent graft rejection primary graft w/o high risk characteristic study 1 ( PKP study ) B . Evaluation efficacy 2 % cyclosporine prevent graft rejection therapeutic keratoplasty- study 2 ( TKP study ) Materials &amp; Methods : In arm Patients require keratoplasty , age 18 satisfactorily meet The inclusion criterion different study Eligible candidate enrol signing Informed Consent form Patients randomize one 2 group - Only topical steroid group A - On topical steroid + 2 % cyclosporine Group B Study design : Prospective , randomize non-blinded study single centre . Methodology In arm 1 . Schedule topical steroid administration : 6 time 2 week ; 5 time 2 week ; 4 time month ; 3 time month , , subsequently twice-a-day 1 year complete Systemic steroid may administer initial 2 week discretion investigator . ( For patient fungal keratitis topical steroid preferrably administer 2 week post keratoplasty . ) Until voveran ophtha may use 3 . Patients randomize receive 2 % cyclosporine receive 3 time day 2years 4 . All patient follow minimum period 2 year 5 . Follow schedule - 1 week , 2 week , 1 month , 2 month , 3 month , every 3 month 2 year complete 6 . All episode graft rejection treat per accepted norm patient longer follow standardize protocol steroid administration</brief_summary>
	<brief_title>Evaluation Efficacy 2 % Cyclosporine Preventing Graft Rejection</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>FOR ARM 1 Age great 18 year Vision 6/60 fellow eye . No prior keratoplasty Not 1 quadrant corneal vascularisation No peripheral anterior synechiae . No active ocular surface disease ( VKC , dry eye , ) Uncontrolled uveitis glaucoma No limbal stem cell failure . No Prior h/o HSV Primarily patient dystrophy , degeneration pseudophakic bullous keratopathy non vascularise non herpetic corneal scar enrol ARM 2 : Inclusion criterion &amp; Those patient medically unresponsive keratitis limbal involvement graft size restrict less 9mm include study . This ensure postoperative issue synechiae , recurrence infection uncontrolled glaucoma affect study . Grafts must also clear end one month surgery patient continue study.. Expected Outcome 1 . Incidence graft rejection arm . 2. secondary outcome Recovery graft rejection arm . 3 . Secondary outcome incidence glaucoma cataract . 4. secondary outcome Incidence graft rejection patient maintain cyclosporine 1year . 5 . It expect patient receive cyclosporine less incidence graft rejection exhibit faster recovery . The efficacy long term prophylaxis cyclosporine prevent graft rejection also evaluate . Any condition would increase risk nonrejection graft failure StevensJohnson syndrome , xerophthalmia severe exposure keratitis . Schirmer 's test â‰¤ 5 mm 1 minute Clinical evidence limbal stem cell deficiency History active herpes simplex virus keratitis acute corneal infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>